Cargando…

The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3

Detalles Bibliográficos
Autores principales:	Sridhar, Vikas S., Heerspink, Hiddo J.L., Davies, Michael J., Banks, Phillip, Girard, Manon, Garg, Satish K., Cherney, David Z.I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2023
Materias:	e-Letter – Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300514/ https://www.ncbi.nlm.nih.gov/pubmed/37172207 http://dx.doi.org/10.2337/dc23-0129

Ejemplares similares

Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2
por: Rodbard, Helena W, et al.
Publicado: (2021)

Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial
por: Baker, Claire, et al.
Publicado: (2019)

Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies
por: Peters, Anne L., et al.
Publicado: (2020)

The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes
por: van Raalte, Daniël H., et al.
Publicado: (2019)

Cardiorenal Protection in Diabetic Kidney Disease
por: Lee, Jason F., et al.
Publicado: (2021)

Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
por: Koufakis, Theocharis, et al.
Publicado: (2021)

Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials
por: Koomen, Jeroen V., et al.
Publicado: (2020)

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
por: Sands, Arthur T., et al.
Publicado: (2015)

Validating the Safe and Effective Use of a Neurorehabilitation System (InTandem) to Improve Walking in the Chronic Stroke Population: Usability Study
por: Smayda, Kirsten Elisabeth, et al.
Publicado: (2023)

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption
por: Powell, David R, et al.
Publicado: (2019)

Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
por: Sridhar, Vikas S., et al.
Publicado: (2020)

OR22-5 Sotagliflozin Decreases Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption
por: Powell, David, et al.
Publicado: (2019)

Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes
por: Bjornstad, Petter, et al.
Publicado: (2018)

Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials
por: Heerspink, Hiddo J.L., et al.
Publicado: (2023)

Unique Tandem Repeats in the Inverted Terminal Repeat Regions of Monkeypox Viruses
por: Desingu, Perumal Arumugam, et al.
Publicado: (2023)

Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study
por: Posch, Maximilian G., et al.
Publicado: (2022)

A review of sotagliflozin for use in type 1 diabetes
por: Nuffer, Wesley, et al.
Publicado: (2019)

The journey from gene knockout to clinical medicine: telotristat and sotagliflozin
por: Rendell, Marc S
Publicado: (2019)

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
por: Cefalo, Chiara Maria Assunta, et al.
Publicado: (2019)

Sotagliflozin attenuates cardiac dysfunction and remodeling in myocardial infarction rats
por: Zhong, Peng, et al.
Publicado: (2023)

Management of Diabetic Ketoacidosis in Severe Insulin Resistance
por: Robinson, Cemre, et al.
Publicado: (2016)

Progress and opportunities in measuring the burden of Chronic Kidney Disease
por: Vart, Priya, et al.
Publicado: (2022)

Sotagliflozin vs Dapagliflozin: A Systematic Review Comparing Cardiovascular Mortality
por: Iyer, Nandhini, et al.
Publicado: (2023)

Differential Functions of Individual Transcription Factor Binding Sites in the Tandem Repeats Found in Clinically Relevant cyp51A Promoters in Aspergillus fumigatus
por: Paul, Sanjoy, et al.
Publicado: (2022)

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
por: Charytan, David M, et al.
Publicado: (2023)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes
por: Powell, David R, et al.
Publicado: (2015)

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects
por: He, Xuemei, et al.
Publicado: (2022)

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?
por: Perco, Paul, et al.
Publicado: (2018)

The Cardiorenal Syndrome
por: Rosner, Mitchell H., et al.
Publicado: (2011)

Cardiorenal syndrome
por: Schetz, Miet
Publicado: (2009)

Cardiorenal syndrome
por: Ye, Wen Qing Wendy, et al.
Publicado: (2023)

Impact of SARS-CoV-2 Spike Mutations on Its Activation by TMPRSS2 and the Alternative TMPRSS13 Protease
por: Stevaert, Annelies, et al.
Publicado: (2022)

Evaluation of clinical outcomes in an interdisciplinary abdominal pain clinic: A retrospective, exploratory review
por: Deacy, Amanda D, et al.
Publicado: (2019)

Opioid and Benzodiazepine Withdrawal Syndromes in Trauma ICU Patients: A Prospective Exploratory Study
por: Arroyo-Novoa, Carmen Mabel, et al.
Publicado: (2020)

Believing processes during the COVID-19 pandemic in individuals with bipolar disorder: An exploratory study
por: Tietz, Sophie, et al.
Publicado: (2022)

Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes
por: Danne, Thomas, et al.
Publicado: (2019)

Preventive Measures for Patients at Risk for Amputation From Diabetes and Peripheral Arterial Disease
por: Goodney, Philip P., et al.
Publicado: (2014)

Virtual Look AHEAD Program: Initial Support for a Partly Virtualized Intensive Lifestyle Intervention in Type 2 Diabetes
por: Williams, Geoffrey C., et al.
Publicado: (2014)

Role of Noninsulin Therapies Alone or in Combination in Chromosome 6q24-Related Transient Neonatal Diabetes: Sulfonylurea Improves but Does Not Always Normalize Insulin Secretion
por: Carmody, David, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ipb43tge8359rm9a2edo7f5bm1